You are here

  • Home
  • Archive
  • Volume 73, Issue 2
  • EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

Article Text

Article menu
Download PDFPDF
Letter
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial
  1. R V Moerman1,
  2. S Arends1,
  3. P M Meiners2,
  4. E Brouwer1,
  5. F K L Spijkervet2,
  6. F G M Kroese1,
  7. A Vissink2,
  8. H Bootsma1
  1. 1 Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  2. 2 Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  1. Correspondence to Dr H Bootsma, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, PO-Box 30.001, Groningen 9700 RB, The Netherlands; h.bootsma{at}umcg.nl

https://doi.org/10.1136/annrheumdis-2013-203736

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rituximab therapy is a promising treatment for primary Sjögren's syndrome (pSS).1 ,2 So far, treatment studies performed in patients with pSS lacked the use of a uniform outcome measure to monitor disease activity.

    Recently, the European League Against Rheumatism (EULAR) developed the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).3 ESSDAI was shown to be able to monitor disease activity in patient profile and open-label studies.4 ,5 To further study the utility of ESSDAI for clinical studies, we assessed the responsiveness of ESSDAI after rituximab treatment in a randomised controlled trial (RCT) of patients with pSS.6

    As the principal investigator (HB) was involved in the development of ESSDAI, the database of a single-centre, randomised, double-blind, placebo-controlled trial (see ref. 6 for details) was prospectively completed with regard to all ESSDAI domains, namely the cutaneous, respiratory, renal, articular, muscular, peripheral and central nervous system, haematological, glandular, constitutional, …

    View Full Text

    Footnotes

    • Contributors All authors contributed to the conception and design or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content and final approval of the version to be published.

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval Ethics committee of the University Medical Center Groningen.

    • Provenance and peer review Not commissioned; externally peer reviewed.